[1] Wan EYF, Mathur S, Zhang R, Yan VKC, Lai FTT, Chui CSL, Li X, Wong CKH, Chan EWY, Yiu KH, Wong ICK. Association of COVID-19 with short- and long-term risk of cardiovascular disease and mortality： a prospective cohort in UK Biobank. Cardiovasc Res. 2023 Jul 6;119(8)：1718-1727. doi： 10.1093/cvr/cvac195. PMID： 36652991.[2]Shang J,Ye G,Shi K,et al. Structural basis of receptorrecognition by SARS- Co V- 2[J]. Nature,2020,581(7807)：221-224.[3]Harmer D,Gilbert M,Borman R,et al. Quantitative m RNAexpression profiling of ACE 2,a novel homologue of angiotensinconverting enzyme[J]. FEBS Lett,2002,532(1-2)：107-110.[4]SOLOMON J J, HEYMAN B, KO J P,et al. CT of Post-Acute Lung Complications of COVID-19[J]. Radiology, 2021, 301(2)： e383-e395.[5]Zhang JJ, Dong X, Cao YY,etc. Clinical characteristics of 140patients infected with SARS-Co V-2 in Wuhan, China. Allergy. 2020 Jul;75(7)：1730-1741. doi： 10.1111/all.14238. Epub 2020 Feb 27.[6]Wu Z, Mc Googan JM： Characteristics of and Important Lessons From theCoronavirus Disease 2019 (COVID-19) Outbreak in China： Summary of aReport of 72 314 Cases From the Chinese Center for Disease Controland Prevention. Jama 2020.[7]Shah W,Hillman T,Playford ED,et al. Managing the long termeffects of COVID-19：summary of NICE,SIGN,and RCGP rapidguideline[J]. BMJ,2021,372：n136.[8]Cares-Marambio K,Montenegro-Jimnez Y,Torres-Castro R,etal. Prevalence of potential respiratory symptoms in survivors ofhospital admission after coronavirus disease 2019(COVID-19)：asystematic review and meta- analysis [J]. Chron Respir Dis,2021,18：14799731211002240.[9]Ge Xing-Yi,Li Jia-Lu,Yang Xing-Lou, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor.[J]. Nature, 2013, 503(7477)：535-8.[10]MISHIMA E,ANAZAI N,MIYAZAKI M,et al.Uric acid elevation by favipiravir,an antiviral drug[J].Tohoku J Exp Med,2020,251( 2) ： 87-90.[11]Konstantinos Pontikis,Ilias Karaiskos,Styliani Bastani,etc.Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria[J].2014,43 (1).[12]Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China： a descriptive study. Lancet, 2020, 395(10223)：507-513.[13]中华预防医学会新型冠状病毒肺炎防控专家组.新型冠状病毒肺炎流行病学特征分析[J].中华流行病学杂志,2020,41(2)：139-144[14]Wan S, Yi Q, Fan S, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). med Rxiv, 2020. [2020-02-21].[15]Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distresssyndrome [J/OL]. Lancet Respir Med, 2020(2020-2-8). https：//doi. org/10. 1016/S2213-2600(20)30076-X.[16]Xie LX, Liu YN, Hao FY, et al. Prognostic analysisof lung function and chest Xray changes of 258 patientswith severe acute respiratory syndrome in rehabilitationafter discharge [J]. Chinese Journal of Tuberculosis andRespiratory Diseases, 2004, 27(3)：147-150.[17]Chen X, Wu Y, Chen C, et al. Identifying potential antiCOVID-19 pharmacological components of traditional Chinese medicine Lianhuaqingwen capsule based on human exposure and ACE2 biochromatography screening. Acta Pharm Sin B, 2021, 11(1)： 222-236.[18]李旷宇,安薇,夏飞等.肺排毒汤加减方联合抗病毒药物治疗新型冠状病毒肺炎的回顾性研究.中草药 http：//kns.cnki.net/kcms/detail/12.1108.R.20200407.1425.011.html.
